1-[3-(methylsulfonyl)propyl]cyclobutanecarboxylic acid | 288616-47-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-[3-(methylsulfonyl)propyl]cyclobutanecarboxylic acid
• 英文别名: 1-(3-Methylsulfonylpropyl)cyclobutane-1-carboxylic acid
• CAS: 288616-47-7
• 化学式: C₉H₁₆O₄S
• 分子量: 220.29
• InChiKey: HJGVCDNQMRXFJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Diephenyl carbocyclic thioamide derivatives
  申请人：——

  公开号：US20010041799A1

  公开（公告）日：2001-11-15

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已发现以下化合物的公式：1及其药学上可接受的盐和酯，其中X和Y的定义如下，能够抑制VCAM-1与VLA-4的结合，并且适用于治疗与慢性炎症性疾病相关的炎症，例如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（I BD）。
• PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES
  申请人：——

  公开号：US20020010338A1

  公开（公告）日：2002-01-24

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已经发现了以下化合物的公式1及其药学上可接受的盐和酯，其中X和Y的定义如下，可以抑制VCAM-1与VLA-4的结合，并且在治疗与慢性炎症性疾病相关的炎症方面非常有用，如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（IBD）。
• Thioamide derivatives
  申请人：——

  公开号：US20020028933A1

  公开（公告）日：2002-03-07

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已经发现了化学式为1的化合物及其药学上可接受的盐和酯，其中X和Y如下定义，可以抑制VCAM-1与VLA-4的结合，并且在治疗与慢性炎症性疾病相关的炎症方面具有用途，例如类风湿性关节炎（RA）、多发性硬化症（MS）、哮喘和炎症性肠病（I BD）。
• Diphenyl heterocyclic thioamide derivatives
  申请人：——

  公开号：US20020040148A1

  公开（公告）日：2002-04-04

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).

  已经发现以下化合物的公式：1及其药学上可接受的盐和酯，其中X和Y的定义如下，可以抑制VCAM-1与VLA-4的结合，并且在治疗与慢性炎症性疾病相关的炎症方面非常有用，例如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（I BD）。
• Heterocyclic thioamide derivatives
  申请人：——

  公开号：US20020052508A1

  公开（公告）日：2002-05-02

  It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (IBD).

  已经发现了以下式子的化合物：1及其药用可接受的盐和酯，其中X和Y的定义如下，可以抑制VCAM-1与VLA-4的结合，并且有助于治疗与慢性炎症性疾病相关的炎症，例如类风湿性关节炎（RA），多发性硬化症（MS），哮喘和炎症性肠病（IBD）。